Jan 25 (Reuters) - Beigene Ltd BGNE.O
* Beigene initiates global Phase III trial of the BTK inhibitor BGB-3111 in Waldenström's Macroglobulinemia
* Beigene Ltd - approximately 170 patients are expected to be enrolled at clinical sites in North America, Europe, Australia, and New Zealand Source text for Eikon: ID:nGNXNOBVNa Further company coverage: BGNE.O